Company profile
Rapport Therapeutics, Inc.
NASDAQ:RAPPBiotechnology: Pharmaceutical Preparations
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07219407 | phase2 | recruiting | 2025-12-15 | 2028-02-03 | Rapport Therapeutics Inc. | A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures |
| NCT07046494 | phase2 | active_not_recruiting | 2025-07-25 | 2026-08-05 | Rapport Therapeutics Inc. | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder |
| NCT07594119 | phase3 | recruiting | 2026-09-01 | 2029-07-01 | Rapport Therapeutics Inc. | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures |
| NCT07563881 | phase3 | recruiting | 2026-06-05 | 2029-07-01 | Rapport Therapeutics Inc. | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 |
| NCT06377930 | phase2 | completed | 2024-10-10 | 2025-09-26 | Rapport Therapeutics Inc. | Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy |
FDA applications (0)
No records yet.